Instil Bio, Inc. (TIL)
NASDAQ: TIL · Real-Time Price · USD
8.85
+0.30 (3.51%)
Mar 6, 2026, 1:32 PM EST - Market open
Instil Bio Employees
Instil Bio had 14 employees as of December 31, 2024. The number of employees decreased by 35 or -71.43% compared to the previous year.
Employees
14
Change (1Y)
-35
Growth (1Y)
-71.43%
Revenue / Employee
n/a
Profits / Employee
-$5,362,571
Market Cap
60.02M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14 | -35 | -71.43% |
| Dec 31, 2023 | 49 | -143 | -74.48% |
| Dec 31, 2022 | 192 | -220 | -53.40% |
| Dec 31, 2021 | 412 | 262 | 174.67% |
| Dec 31, 2020 | 150 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 148 |
| ImmuCell | 84 |
| InflaRx | 74 |
| Mereo BioPharma Group | 36 |
| eXoZymes | 31 |
| Q32 Bio | 26 |
| NeurAxis | 21 |
| Rallybio | 15 |
TIL News
- 2 months ago - Instil Bio Pulls Plug On Lead Drug Development - Benzinga
- 2 months ago - Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco - GlobeNewsWire
- 4 months ago - Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - Instil Bio Announces ImmuneOnco's Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC) - GlobeNewsWire
- 7 months ago - Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 months ago - ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China - GlobeNewsWire
- 8 months ago - Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors - GlobeNewsWire
- 9 months ago - Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program - GlobeNewsWire